1. A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. (1st January 2020) Authors: Somaiah, Neeta; Chawla, Sant P.; Block, Matthew S.; Morris, John C.; Do, Khanh; Kim, Joseph W.; Druta, Mihaela; Sankhala, Kamalesh K.; Hwu, Patrick; Jones, Robin L.; Gnjatic, Sacha; Kim-Schulze, Seunghee; Tuballes, Kevin; Yishak, Mahlet; Lu, Hailing; Yakovich, Adam; Ter Meulen, Jan; Chen, Michael... Journal: Oncoimmunology Issue: Volume 9:Number 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗